BackEnorama Pharma AB (publ) Overview

Enorama Pharma AB (publ) Current Assets

Track Enorama Pharma AB (publ)'s current assets ($6.9M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$6.87M
↓ 22.81% YoYΔ $-2.03M vs prior year quarter

Peer trimmed avg / median

Loading

Enorama Pharma AB (publ) Current Assets History

Loading

Enorama Pharma AB (publ) vs. peers: Current Assets Comparison

Loading

Enorama Pharma AB (publ) Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Enorama Pharma AB (publ) (ERMA.ST) FAQ

Enorama Pharma AB (publ) posts a current assets of $6.9M as of June 2026. That compares with $8.9M in the prior-year period — down 22.8% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Enorama Pharma AB (publ)'s current assets was $8.9M. The latest reading is $6.9M — a 22.8% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Current Assets is one piece of Enorama Pharma AB (publ)'s financial statement story. At $6.9M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ERMA.ST's current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Enorama Pharma AB (publ)'s other metric pages and overview cover the third.